(6S)-N,N'-Dipropyl-4,5,6,7-Tetrahydro-1,3-Benzothiazole-2,6-Diamine

Within a cGMP kilo-lab campaign dedicated to pramipexole dihydrochloride monohydrate process validation, gram-to-kilogram batches of (6S)-N,N′-dipropyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine are routinely manufactured as the primary related-substances marker. The compound is not a process intermediate per se but the predominant over-alkylation by-product formed when excess propionaldehyde is present during the reductive amination of (6S)-2,6-diamino-4,5,6,7-tetrahydro-1,3-benzothiazole. Its isolation and structural certification according to ICH Q7 therefore become a mandatory gatekeeping step before HPLC method qualification. In a representative 20-L jacketed glass reactor purged with nitrogen to maintain an oxygen level below 0.5%, (6S)-2,6-diamino-4,5,6,7-tetrahydro-1,3-benzothiazole dihydrochloride (1.0 mol) is suspended in anhydrous methanol (8.0 L) and cooled to -5 °C ± 2 °C. A solution of propionaldehyde (2.2 mol) in dry tetrahydrofuran (2.5 L) is metered in over 90 minutes while the slurry is maintained under a nitrogen sweep. After a 15-minute pre-stir, sodium cyanoborohydride (2.4 mol) dissolved in methanol (1.2 L) is dosed via a peristaltic pump at a rate that keeps the internal temperature below 0 °C. The heterogeneous mixture is then allowed to warm to 22 °C over 2 hours and held for an additional 6 hours with vigorous agitation at 350 rpm, during which the target (6S)-N,N′-dipropyl impurity is formed in parallel with the mono-propyl pramipexole base. Quenching is executed by slow addition of aqueous ammonia (25% w/w, 1.5 L) at 5 °C, and the crude free base is extracted with ethyl acetate (3 × 4.0 L). The combined organic layers are washed with deionized water (2 × 2.0 L), dried over anhydrous sodium sulfate, and concentrated under reduced pressure at 35 °C using a Büchi Rotavapor R-220 with a vacuum set point of 20 mbar. The oily residue is triturated in diisopropyl ether (2.5 L) and then crystallized from diisopropyl ether/n-heptane (1:3 v/v, 5.0 L) by slow cooling from 50 °C to -10 °C at a ramp of 0.25 °C/min. The resulting off-white crystalline solid is filtered through a Nutsche filter, washed with chilled n-heptane, and dried in a vacuum tray dryer at 30 °C and ≤5 mbar for 24 hours to yield the (6S)-N,N′-dipropyl free base with a chromatographic purity of ≥99.5% (HPLC, UV detection at 210 nm, area normalization). Chiral purity, determined on a Chiralpak IA-3 column (4.6 × 250 mm, mobile phase: n-hexane/ethanol/diethylamine 90:10:0.1), routinely exceeds 99.0% ee. The identity is confirmed by ¹H and ¹³C NMR, high-resolution mass spectrometry, and differential scanning calorimetry (onset of melting endotherm: 82.5 °C ± 0.8 °C). The material is sub-packaged in amber glass vials under argon and stored at −20 °C for use as a working standard during process development campaigns. Residual solvent analysis according to USP 〈467〉 Class 3 limits verifies that methanol, tetrahydrofuran, and heptane remain below 0.5% each. Heavy metal content is verified by inductively coupled plasma mass spectrometry to stay below 10 ppm for Pd, Ni, and Cu, thereby meeting ICH Q3D requirements for parenteral-grade impurity markers. This synthetic protocol is employed without change when the campaign shifts from the kilo-lab to a pilot-plant 100-L Hastelloy C-22 reactor, although the agitation speed is reduced to 180 rpm to compensate for the larger blade diameter, and the filtration step is replaced with an agitated Nutsche filter-dryer. Operational controls that are tightened at scale include the dew point of the nitrogen blanket (set point −40 °C or lower) and the oxygen content in the inerted headspace, which must be verified by a Servomex O₂ analyzer to remain below 0.4% before charging propionaldehyde. Any deviation from the 0.25 °C/min cooling ramp during crystallization has been observed to generate a popcorn-like polymorph that retains 1.2–1.8% residual diisopropyl ether, necessitating re-slurrying and an additional product-drying cycle.

What residual solvent profile emerges when the crystalline free base is prepared under a modified ICH Q3C option 2 approach?

The polymorph landscape of the (6S)-N,N′-dipropyl derivative exerts a direct influence on the desolvation kinetics encountered during vacuum drying. When the primary crystallization solvent pair is switched from diisopropyl ether/heptane to ethyl acetate/cyclohexane (1:5 v/v) to lower the concentration of peroxide-forming solvents, the resulting needle-like crystals exhibit a residual ethyl acetate content of 0.8–1.2% after 16 hours at 30 °C and 10 mbar. A programmed drying ramp consisting of a 4-hour hold at 20 °C, followed by a step to 40 °C for 8 hours and a final polishing step at 50 °C for 4 hours, all at ≤5 mbar, reduces ethyl acetate to <0.1% and cyclohexane to <0.05%. This profile is verified using headspace gas chromatography with a flame ionization detector on an Agilent 7697A/7890B system fitted with a DB-624 column (30 m × 0.32 mm, 1.8 µm film). The injection port is set to 200 °C with a split ratio of 5:1, and the oven is programmed from 40 °C (hold 5 min) to 220 °C at 20 °C/min. Helium carrier gas is maintained at a constant flow of 2.0 mL/min. The method achieves a limit of quantification of 5 ppm for ethyl acetate and 2 ppm for cyclohexane, satisfying USP 〈467〉 procedure A. Importantly, the needle polymorph generated by the ethyl acetate/cyclohexane system displays a ~1.5-fold higher dissolution rate in 0.1 N HCl than the block-shaped crystals obtained from diisopropyl ether/heptane, a property that becomes relevant when the standard is used as a dissolution calibrator for pramipexole extended-release tablets tested per USP General Chapter 〈711〉. Operators in the analytical development laboratory record that the ethyl acetate/cyclohexane lot must be sieved through a 125-µm stainless-steel mesh and any fraction below 45 µm discarded because fines promote oxidative degradation of the aminothiazole ring during long-term storage, as evidenced by a 0.15% increase in the total aerobic microbial count surrogate (specified as <0.1% for the oxidised dimer impurity). All headspace vials are crimped with PTFE-lined septa that have been pre-conditioned at 105 °C for 2 hours to eliminate interfering volatiles, and each sequence includes a continuing calibration verification standard at the midpoint of the linear range (0.1% w/w for each solvent).

When Palladium Acetate Meets (6S)-N,N′-Dipropyl-2,6-diamine in Asymmetric Suzuki Couplings

The (6S)-enantiomer of this N,N′-dipropyl diamine functions as a bidentate chiral ligand for palladium-catalyzed cross-coupling reactions that require enantiodiscrimination at a nascent C–C bond. In a nitrogen-filled MBraun glovebox maintaining O₂ and H₂O levels below 1 ppm, palladium(II) acetate (0.5 mol% with respect to the aryl bromide) and the diamine (0.55 mol%, to ensure a slight ligand excess) are stirred in anhydrous toluene (10 mL per mmol of substrate) at 25 °C for 45 minutes. The immediate formation of a pale-yellow, air-sensitive Pd–diamine complex is monitored by in situ ReactIR, which reveals the disappearance of the free acetate carbonyl stretch at 1615 cm⁻¹ and the emergence of a coordinated amine band at 568 cm⁻¹. The preformed catalyst solution is transferred via cannula to a Schlenk flask charged with the aryl bromide (1.0 equiv), the boronic acid (1.3 equiv), and powdered anhydrous potassium carbonate (3.0 equiv). Degassed water (1.0 mL per mmol) is added, and the biphasic mixture is heated to 80 °C under vigorous stirring (1200 rpm) for 12 hours. After cooling, the organic phase is separated, washed with brine, and concentrated, and the enantiomeric excess is determined on a Daicel Chiralcel OD-H column with n-hexane/isopropanol (95:5) at 1.0 mL/min. Across a set of 14 electronically diverse aryl bromides, the enantiomeric excess of the biaryl product ranges from 88% to 95%, with electron-deficient substrates typically delivering the highest selectivity. Precise stoichiometric control is critical; using the ligand at substoichiometric levels (0.4 mol% relative to Pd) causes racemisation within 4 hours, whereas exceeding 0.7 mol% suppresses turnover frequency without improving ee. During scale-up to a 500-mL reactor, the thermal signature of the exothermic catalyst formation step is managed by jacketed cooling at 18 °C, and the potassium carbonate is slurried in water before addition to avoid local hot spots that can decompose the ligand. The recovered aqueous layer from three consecutive reactions is treated with activated carbon and the diamine ligand is re-extracted as the hydrochloride salt; repurification gives a recovered ligand with ≥97% chiral purity, enabling a cost model in which the ligand cost per gram of isolated biaryl product is ≤USD 12 when translated to a 100-kg active pharmaceutical ingredient campaign. All biaryl products are isolated by flash chromatography on silica gel 60 (Merck grade, 230–400 mesh) using a heptane/ethyl acetate gradient and are structurally confirmed by X-ray crystallography with a Flack parameter refined to within 0.02(3).

The chiral diamine is also examined in the asymmetric α-arylation of ketones. Using conditions adapted from Buchwald’s procedures, the diamine (1.2 mol%) and Pd₂(dba)₃ (0.5 mol%) are combined in tetrahydrofuran at 40 °C with sodium tert-butoxide (1.5 equiv) and 2-bromotoluene (1.0 equiv), yielding the corresponding tetralone with an enantiomeric excess of up to 82%. The diamine’s performance in this context is sharply attenuated when the solvent contains more than 50 ppm water, making rigorous solvent drying over 3Å molecular sieves a prerequisite. A separate limitation surfaces when electron-rich, sterically hindered aryl bromides such as 2,6-dimethylbromobenzene are employed; the yield drops below 30% and the ee collapses to <10%, a boundary that has been mapped using a Design of Experiments matrix comprising 36 distinct substrate-ligand-metal combinations. The ligand is incompatible with copper(I) salts, which displace palladium within 60 minutes at room temperature and form a catalytically inert Cu-bis(diamine) complex. For larger-scale batch manufacture, the preferred reactor material is glass-lined steel; 316L stainless steel vessels cause a progressive decline in ee (~2% per 8-hour cycle) attributable to trace iron extracted from the vessel wall, as confirmed by ICP-OES analysis of the reaction mixture showing 15–20 ppm Fe after 24 hours.

When a 0.10% Area Threshold Determines Batch Release of Pramipexole Dihydrochloride Drug Substance

Regulatory compendia designate (6S)-N,N′-dipropyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine as Impurity C in the pramipexole dihydrochloride monohydrate monograph. The current European Pharmacopoeia 11.0 (monograph 2416) limits this impurity to ≤0.10% by HPLC area normalization, while the United States Pharmacopeia (USP-NF 2024, Issue 1) lists an acceptance criterion of NMT 0.10% under the organic impurities test. The analytical method specified in both compendia employs an octadecylsilane chemically bonded silica column (4.6 mm × 150 mm, 5 µm particle size) maintained at 30 °C, with a mobile phase consisting of phosphate buffer (pH 2.5 adjusted with phosphoric acid) and acetonitrile in a gradient from 95:5 to 60:40 over 35 minutes. The flow rate is 1.0 mL/min and the injection volume is 20 µL. Detection is at 262 nm, at which the relative response factor of Impurity C versus pramipexole is 1.08. For system suitability, a resolution solution containing pramipexole and the (6S)-dipropyl impurity at 0.5 µg/mL each must yield a resolution of ≥2.5 between the two peaks. The retention time of the impurity relative to pramipexole is typically 1.25 ± 0.05. To prepare working standard stock solutions, accurately weighed portions of the (6S)-N,N′-dipropyl impurity reference standard are dissolved in a mixture of water and acetonitrile (80:20 v/v) at a concentration of 100 µg/mL, followed by dilution to 1 µg/mL for the standard curve. The calibration function is linear across the range 0.1–5.0 µg/mL (r² > 0.999), and the reporting threshold is 0.02%. Any pramipexole batch that records an impurity C peak area exceeding 0.07% in the initial test is flagged for a retest under repeatability conditions (n = 6), and if confirmed, the lot is routed to a re-purification stream comprising preparative HPLC on a C18 column with a loading of 5 g/L of stationary phase and a mobile phase of 0.1% trifluoroacetic acid in acetonitrile/water (25:75). The re-purification is repeated until the impurity C content is lowered below 0.03%, a level that typically ensures compliance even after 36 months of storage at 25 °C/60% RH in HDPE drums lined with a double low-density polyethylene bag. Stability chambers operated at 40 °C/75% RH for 6 months have not shown any growth of this impurity, confirming that it is a process impurity, not a degradation product. In routine quality control at a contract manufacturing organization, the (6S)-N,N′-dipropyl standard is handled inside an ISO 14644-1 Class 8 cleanroom, with on-balance weighing carried out on a Mettler Toledo XPR205 balance (readability 0.01 mg, minimum sample weight per USP 〈41〉 is 15.0 mg). Each new lot of impurity reference standard is co-quantified against the previous lot using an external standard method to detect any concentration drift exceeding 1.0%.

Radioligand displacement studies conducted on transfected Chinese hamster ovary cell membranes expressing human dopamine D2S and D3 receptors have mapped the binding signature of the (6S)-N,N′-dipropyl derivative. Using [³H]spiperone as the hot ligand at a concentration of 0.5 nM, the compound displaces specific binding with a mean inhibition constant (Kᵢ) of 12.4 nM at D3 and 890 nM at D2, yielding a D2/D3 selectivity ratio of ~72. This pharmacological fingerprint is exploited in preclinical neuroscience laboratories to dissect D3-mediated signalling pathways in mesolimbic projection areas without concurrent D2 autoreceptor activation that would confound the readout. In a microdialysis setup performed on freely moving Sprague-Dawley rats dosed at 1.0 mg/kg intraperitoneally, the compound elevates extracellular dopamine in the nucleus accumbens shell by 280% over baseline within 60 minutes, an effect that is blocked by pretreatment with the D3-selective antagonist SB-277011-A (10 mg/kg i.p.). Differentiated neuro-2a cells treated with the compound at 10 µM for 48 hours show a 1.8-fold increase in β-arrestin-2 recruitment measured by bioluminescence resonance energy transfer, corroborating a bias toward G-protein-independent signalling. For in vivo distribution, a stock solution is prepared in sterile saline acidified with 0.1 N HCl to a final pH of 4.5 and dosed within 20 minutes to avoid oxidative cyclisation that generates a quinone-imine species visible as a pink chromophore. The same formulation, when left at ambient light for 4 hours, loses ~15% of its potency as determined by a re-assay on the D3 receptor. Because of this photolability, all surgical implantation of osmotic minipumps (Alzet model 2004, delivering 0.25 µL/h for 28 days) must be performed under a sodium-vapour darkroom lamp, and the pump reservoir is wrapped in aluminium foil. The compound does not cross the blood-brain barrier in sufficient quantity when administered orally as the free base; the absolute oral bioavailability in rat is <5%, a limitation that restricts its use to parenteral routes in exploratory pharmacology and confirms why this N,N′-dipropyl derivative was not progressed as a clinical candidate despite its promising D3 selectivity profile.

A Convergent Route to 2,6-Disubstituted Benzothiazole Dopamine Agonists

The (6S)-N,N′-dipropyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine scaffold serves as a starting point for structure-activity relationship expansions in which the 2-amino position is selectively derivatized while the 6-(propylamino) centre is retained. In a sequence validated at 200-g scale, the free base is first protected as the tert-butoxycarbonyl (Boc) derivative at the 6-propylamine nitrogen by treatment with di-tert-butyl dicarbonate (1.05 equiv) in dichloromethane in the presence of triethylamine (1.2 equiv) at 0 °C, giving an intermediate that is purified by silica gel chromatography. The remaining 2-amino group is then alkylated with 2-bromo-N-methylacetamide (1.3 equiv) in dimethylformamide containing powdered potassium carbonate (3.0 equiv) at 60 °C for 8 hours. After aqueous work-up, the Boc group is removed with trifluoroacetic acid (20% v/v in dichloromethane, 2-hour reaction time), and the free base is re-crystallised from ethanol/diethyl ether (1:10) to afford the target 2-(2-methylamino-2-oxoethyl)-substituted pramipexole analogue in 67% overall yield and ≥98.7% purity. A parallel diversification route exploits a one-pot reductive amination of the 2-amino group with 4-methoxybenzaldehyde (1.0 equiv) and sodium triacetoxyborohydride (1.5 equiv) in 1,2-dichloroethane at 25 °C for 16 hours to install a 4-methoxybenzyl group on the thiazole nitrogen. The library generated through these orthogonal transformations is screened against dopamine D3 and D4 receptor subtypes in a cAMP inhibition functional assay calibrated with a EC₅₀ reference of 1.2 μM for quinpirole. One fluorinated derivative produces a D3 EC₅₀ of 28 nM and a D4 EC₅₀ of >10,000 nM, a selectivity window that is maintained in microsomal stability tests (human liver microsomes, intrinsic clearance 22 µL/min/mg, half-life > 120 min). Process safety review before scale-up identified that the 2-bromo-N-methylacetamide alkylation must be operated with an emergency quench protocol because of the lachrymatory and alkylating potential of the reagent; all charging is performed in a glovebag, and the reactor is vented through a scrubbing system charged with 10% aqueous sodium hydroxide. Differential scanning calorimetry on the reaction mixture after reagent addition shows an exotherm onset at 85 °C with an enthalpy of −450 J/g, which requires the reactor jacket to be interlocked with the temperature controller to trigger emergency cooling at 65 °C.